Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRP2-targeted alphavaccine
- Development stage
- Unknown
- Lead developer
- AlphaVax
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
TRP2-targeted alphavaccine is a viral replicon particle (VRP) cancer vaccine developed by AlphaVax for the treatment of melanoma. The vaccine utilizes a propagation-defective Venezuelan Equine Encephalitis (VEE) virus vector to deliver mRNA encoding the tyrosinase-related protein 2 (TRP2) tumor antigen. TRP2 is a membrane-bound enzyme involved in melanin synthesis that is highly expressed in both normal melanocytes and melanoma cells. Upon administration, the VRPs infect dendritic cells, leading to the expression of TRP2 and the subsequent induction of a potent, antigen-specific T-cell immune response designed to recognize and eliminate melanoma cells. The program has been evaluated in Phase 1 clinical trials to assess safety and immunogenicity in patients with advanced melanoma.
- Other names
- TRP2 alphavaccineTRP-2 alphavaccineTRP 2 alphavaccineTyrosinase-related protein 2 alphavaccineTRP2-targeted VRP vaccineTRP-2-targeted VRP vaccineTRP 2-targeted VRP vaccineVenezuelan equine encephalitis virus replicon particles encoding TRP2Dopachrome tautomerase alphavaccine
02
Targets
Tyrosinase-related protein 2-specific CD8-positive T cellFCGR3B (Fc gamma receptor III)TYRP2 (Tyrosinase-related Protein 2)
Beyond the preview
Go deeper on TRP2-targeted alphavaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRP2-targeted alphavaccine.